Summary & Overview
HCPCS J9312: Rituximab Injection, 10 mg
HCPCS Level II code J9312 denotes a 10 mg unit of rituximab administered by injection or infusion. Rituximab is a monoclonal antibody widely used in oncology and certain autoimmune disorders; billing for this drug is important for cost accounting, medication utilization tracking, and reimbursement workflows across outpatient and infusion settings. Nationally, accurate coding of drug units affects drug pass-through payments, outpatient prospective payment calculations, and coverage determinations.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical role and service settings, typical payer coverage considerations, and the types of benchmarks and policy updates that affect utilization and payment for injectable oncology biologics. The publication summarizes how J9312 is used on service lines, common billing modifiers associated with injectable drugs, and where to look for payer-specific guidance.
This analysis is written for a national audience and focuses on operational and policy-relevant facts: what the code represents, the settings where it is typically billed, payer coverage landscape, and the categories of documentation and billing practice that influence reimbursement and compliance.
Billing Code Overview
HCPCS Level II code J9312 represents injection, rituximab, 10 mg. This code denotes a parenteral infusion or injection medication supply measured in 10 mg units of rituximab, a monoclonal antibody used in oncology and certain autoimmune conditions.
-
Service type: Injectable biologic medication administration and drug supply
-
Typical site of service: Hospital outpatient department, physician office infusion suite, or ambulatory infusion center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a B‑cell mediated hematologic malignancy or an autoimmune disorder scheduled to receive intravenous rituximab therapy. The billing code J9312 represents rituximab dosed and billed per 10 mg units; actual dosing is weight‑based or fixed per indication (for example, 375 mg/m2 for non‑Hodgkin lymphoma or 1000 mg IV for certain rheumatoid arthritis regimens). The patient arrives to an outpatient infusion center or hospital outpatient department, is registered, screened for infusion reaction risk and baseline labs (CBC, CMP, and hepatitis B serologies when indicated), and is assessed by an infusion nurse. Pre‑medications such as acetaminophen, an antihistamine, and a corticosteroid may be administered. The pharmacy prepares the rituximab infusion, documented by lot number and concentration. The infusion is started under nursing monitoring with vital signs at baseline and at regular intervals; infusion rate is titrated per institutional protocol and product labeling. Any infusion reactions, dose modifications, or medication waste (remaining drug not administered) are documented. At discharge the patient receives post‑infusion instructions and follow‑up appointments for subsequent cycles or evaluation. Typical site of service: outpatient infusion center, physician office infusion suite, or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |